Sunday, 8 September 2024
  
Login

Australia's most trusted
source of pharma news

Sunday, 08 September 2024
Listen to this story 
News

Bracing for a $100M revenue hit

Posted 24 July 2024 AM

By the end of July a $397 million blockbuster will be off patent in Australia, and the first biosimilar is primed for launch.

Johnson & Johnson's monoclonal antibody Stelara is set to lose patent protection in Australia on 28 July, mirroring the loss of exclusivity in Europe where the pharma giant expects to greet biosimilar competition in the last week of the month. Although its US patents expired last year, as a result of settlements and agreements J&J does not expect competition in that country until the start of 2025.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (22)

Clinical & Medical, R&D (13)

Regulatory, Pharmacovigilance & QA (6)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.